linjc16/ctgov huggingface dataset:
Markers of Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

Detailed Description
-----------------
Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. However, opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and therefore not detected at the time of stroke. In addition, even when AF is identified anticoagulation may not be initiated due to perceived contraindications. This study will (1) evaluate whether a gene marker can improve the identification of AF in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate AF, and whether this decision could be improved by a marker of AF at time of stroke. An AF Gene Score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid identification of stroke due to AF which may increase initiation of anticoagulation therapy. This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed AF with initial stroke and delays anticoagulation.

Official Title
-----------------
Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate

Conditions
-----------------
Stroke, Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic stroke within 72 hours of onset Complete evaluation to determine cause of stroke Informed Consent Exclusion Criteria: Active Infection Lymphoma / Leukemia / Blood dyscrasia Hemorrhagic stroke Immunosuppressive therapy Illicit drug use Blood transfusion +/- 1 month Major surgery/trauma in last 6mts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atrial fibrillation stroke<br> | |
| Non-atrial fibrillation Stroke<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene expression |  | Post stroke through study completion, an average of 1 year |
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID.

Official Title
-----------------
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France

Conditions
-----------------
Gastrointestinal Hemorrhage, Ulcer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer confirmed by endoscopy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastroprotective agent compliance |  | At the end of 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical characteristics of those ulcers with NSAID |  | At the end of 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Compliance, France, Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID
Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution Magnetic Resonance (MR) Imaging Findings

Study Overview
=================
Brief Summary
-----------------
To clarify whether amnesia after treatment of anterior communicating aneurysm (ACoA)is related to infarcts caused by occlusion or damage of the perforating artery of the ACoA, we used 3.0-T 3D high resolution MR imaging to identify and localize infarcts in patients with amnesia following treatment of ACoA aneurysm.

Detailed Description
-----------------
Cohort register is made by experienced neuropsychologists in our institute. MR imaging and data storage is in the department of diagnostic radiology of our institute. MR images are evaluated by two neuroradiologists using a work station.

Official Title
-----------------
Basal Forebrain Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution 3-dimensional (3D) Magnetic Resonance (MR) Imaging Findings

Conditions
-----------------
Subarachnoid Hemorrhage, Cerebral Aneurysm, Amnesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Amnesia Exclusion Criteria: Severe decreased intellectual function
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cerebral infarction identified and localized in the basal forebrain on MR imaging |  | within 15 months from the aneurysmal treatment(an expected average 4 months) |
Clinical Validation Study of RTVue Features

Study Overview
=================
Brief Summary
-----------------
To perform a clinical validation study of RTVue features in volunteers with various ocular pathology or no ocular pathology.

Detailed Description
-----------------
Clinical validation study of RTVue features in volunteers with various ocular pathology or no ocular pathology. Subjects to undergo a clinical exam and OCT scanning.

Official Title
-----------------
Clinical Validation Study of RTVue Features

Conditions
-----------------
Healthy, Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects will have normal results from the clinical exam and be free of ocular pathology. Glaucoma patients will have clinical exam results consistent with glaucoma; they will have visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma. Retina patients will have clinical exam results consistent with retina pathology. Exclusion Criteria: Normal subjects will be free of any ocular pathology. Glaucoma patients will be free of any ocular pathology except glaucoma. Retina patients will be free of any ocular pathology except any type of retina pathology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal<br>Normal results from the clinical exam and free of ocular pathology. | |
| Glaucoma<br>Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma. | |
| Retina<br>Clinical exam results consistent with retina pathology. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retina measurement |  | at time of study visit (day 1) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retina pathology
Study of Glaucoma Treatment With Food Additives

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if certain food additives are effective in the treatment of glaucoma, improving and reversing the progress of the disease.

Detailed Description
-----------------
Glaucomatous neuropathy is a condition that worsens with time causing atrophy of the optic nerve and narrowing of the visual field which may culminate in blindness. The treatment tested in the trial employs certain food additives intended to reverse this pathology.

Official Title
-----------------
Treatment of Glaucomatous Neuropathy With Food Additives

Conditions
-----------------
Glaucomatous Neuropathy

Intervention / Treatment
-----------------
* Drug: Vitamins, minerals and medical herbs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable open angle glaucoma - with equilibrated eye internal pressure Above the age of 50 years and have severe damage that does not progress to the vision field in the upper and lower half. Scoring of the vision field will be made according to the Agis study instructions. Exclusion Criteria: Eye diseases excluding past cataract operation Allergy to one of the components in the preparation Deterioration in the vision field in the last year Kidney diseases, gastrointestinal (G.I.) tract, liver diseases, coagulation problems and thyroid diseases Persons who take steroids Diabetics or unbalanced hyperglycemia Autoimmune diseases Hypertension (not responding to treatment) Psychiatric treatment with drugs, psychiatric pathologies Pregnancy Ability to take more than 3 pills per day regularly Smoking

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vitamins, minerals and medical herbs|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in vision field (Protocol24) in a Humphrey's instrument. Scoring according to the Agis study |  |  |
Cross-sectional Examination of the Reliability of Oral Implants

Study Overview
=================
Brief Summary
-----------------
Aim of the multi centrical, cross-sectional study is the registration of the prevalence and incidence of mucositis and periimplantitis.

Detailed Description
-----------------
Aim of the multi centrical, cross-sectional study is the registration of the prevalence and incidence of mucositis and periimplantitis. Additional clinical examination of the tolerance of titanium using cytosine analysis of periimplant sulcus smear and of blood lymphocytes on titanium plates in vitro. In total 10 centers will examine clinical, genetic and microbiological parameters in 200 patients during 12 months. Study hypothesis: The incidence of mucositis and periimplantitis during a time period of 10 years in patients is less than 30%

Official Title
-----------------
Cross-sectional Examination of the Reliability of Oral Implants

Conditions
-----------------
Periimplantitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with oral implants inserted after 01.04.2002 Periodical recall Exclusion Criteria: No other titanium implants inside the body

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-1ß | Interleucin 1 beta in peripheral blood | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MMP-8 | Metallomatrixproteinase-8 in Periodontal Sulcus Fluid | 6 month | 
| BOP | Bleeding on probing | 6 months | 
| PD | Probing Depth | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peri-implant disease prevalence incidence tolerance titanium
Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial

Study Overview
=================
Brief Summary
-----------------
The aims of this study are (1) to examine the effect of smoking reduction intervention (reduction counseling and nicotine replacement therapy, NRT) (a) on smoking cessation and (b) on reducing daily cigarette consumption among smokers not willing to quit smoking but want to reduce smoking, and (2) to examine the effect of adherence intervention in producing a higher (a) adherence rate, (b) reduction rate, and (c) quit rate.

Official Title
-----------------
Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Procedure: Reduction Intervention + Adherence Intervention
* Behavioral: Reduction Intervention
* Procedure: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or above Ethnic Chinese male or female Smokes at least 2 cigarettes per day Have no intention to quit in the near future Intends to reduce smoking in the next 7 days Has no contraindication to NRT Exclusion Criteria: Subjects who are psychologically or physically unable to communicate Children and teenagers (age below 18) Pregnant or intention to become pregnant within the next 6 months Those on regular psychotropic medications and in the presence of any serious health problems that may make them unsuitable for using NRT, such as recent stroke, palpitation, or other life threatening conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Reduction Intervention + Adherence Intervention|nan|
|Behavioral: Reduction Intervention|nan|
|Procedure: control|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quit rate |  | 6 months | 
| Reduction Rate (reduction of cigarette consumption by at least 50% compared with baseline) |  | 6 months | 
| Adherence Rate to NRT |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validated quit rate (by measuring exhaled CO and urinary cotinine level) |  | 6 months | 
| Quit rate without validation |  | 1 month | 
| self-reported use of NRT for at least 4 weeks or 8 weeks, without cotinine validation |  | 1 month / 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smokers who are not willing to quit in the near future but intend to reduce smoking
Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy

Study Overview
=================
Brief Summary
-----------------
Non-randomized study of 5 subjects that have been selected for prophylactic open surgery due to abdominal aortic aneurysm. During surgery the renal arteries are identified and subjected to about 60 seconds each of freezing by application of liquid nitrogen in dedicated catheters around the circumference of each artery. Another 5 patients that are not subjected to the freeze therapy serve as controls. Main outcome is change in ambulatory blood pressure levels.

Detailed Description
-----------------
Non-randomized study of 5 subjects that have been selected for prophylactic open surgery due to abdominal aortic aneurysm. During the surgery the renal arteries at both sides are identified and subjected to about 60 seconds each of freezing by application of liquid nitrogen in dedicated catheters around the circumference of each artery. Renal arterial blood flow is checked by Doppler after the freezing procedure, during the surgery. Another 5 patients that are not subjected to the freeze therapy serve as controls. Main outcome is change in 24h ambulatory blood pressure levels and of course safety parameters such as creatinine levels.

Official Title
-----------------
Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy During Open Surgery for Aortic Aneurysm

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Procedure: Cryo-therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: planned prophylactic surgery for abdominal aortic aneurysm Exclusion Criteria: hypotension, inability to understand study protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cryo-therapy<br>Cryo-therapy of renal arteries | Procedure: Cryo-therapy<br>* Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery<br>|
| No Intervention: Control<br>No intervention in renal arteries | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure levels | 24 hour mean ambulatory blood pressure levels before and 2 months after surgery | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of epinephrine and nor-epinephrine in urine | Collection of urine for analyses of stress hormones | before and 2 months after surgery |
Study of MRA in Patients With Rheumatoid Arthritis (RA)

Study Overview
=================
Brief Summary
-----------------
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.

Official Title
-----------------
An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: MRA(Tocilizumab)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients administered MRA more than 2 times in preceding study, MRA009JP, and evaluated the efficacy and the safety. Patients confirmed to have shown the safety in the preceding study. Exclusion Criteria: Patients with Class IV Steinbrocker functional activity at evaluation within 4 weeks before treatment with the study drug Patients who received any of the following treatments between the start of preceding study and the registration of this study. Plasma exchange therapy Surgical treatment (e.g., operation)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: MRA(Tocilizumab)<br>* 8mg/kg/4 weeks for 1 year<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACR 20% responder rate compared to the pre-treatment in the preceding study |  | throughout study | 
| Frequency and severity of adverse events and adverse drug reactions |  | week0,week4,week8,week12,and LOBS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time course of DAS28,compared to the pre-treatment in the preceding study |  | week 0,week 4,week 8,week 12, LOBS | 
| Time course of the ACR 20%, 50%, and 70% responder rates compared to the pre-treatment in the preceding study |  | week 0,week 4,week 8,week 12, LOBS | 
| ACR N AUC compared to the pre-treatment in the preceding study |  | week 0,week 4,week 8,week 12, LOBS | 
| Time course of the ACR core set variables compared to the pre-treatment in the preceding study |  | week 0,week 4,week 8,week 12, LOBS |